Professor, Medicine, University of Pittsburgh School of Medicine
Hematology
Dr. Margaret V. Ragni, MD
|
|
Give Review
Doctor Margaret V. Ragni, MD works in the field of Hematology. She studied medicine at University of Pittsburgh School of Medicine. Margaret V. Ragni, MD is a published doctor and has 50 publications published. The lastest was: 'Prospective, multicenter study of postoperative deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery.' She is registered with Medicare and accepts Medicare payments.
Publications
- Validation Study of the Composite Score to Identify Von Willebrand Disease in Children.
- Long-acting recombinant factor VIII Fc fusion protein (rFVIIIFc) for perioperative haemostatic management in severe haemophilia A.
- Von Willebrand factor for menorrhagia: a survey and literature review.
- Clinical and laboratory variability in a cohort of patients diagnosed with type 1 VWD in the United States.
- Von Willebrand disease in the emergency department.
- Does deficiency of von Willebrand factor protect against cardiovascular disease? Analysis of a national discharge register.
- Inhibitor recurrence after immune tolerance induction: a multicenter retrospective cohort study.
- Thrombin generation and bleeding in haemophilia inhibitor patients during immune tolerance induction.
- Hemostatic efficacy, safety and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease.
- Postpartum haemorrhage in women with von Willebrand disease: an observational study of the Pennsylvania Health Care Cost Containment Council (PHC4) database.
- Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
- Postpartum von Willebrand factor levels in women with and without von Willebrand disease and implications for prophylaxis.
- Venous thromboembolism in pregnant women with sickle cell Disease: A retrospective database analysis.
- Switching to recombinant factor IX Fc fusion protein prophylaxis results in fewer infusions, decreased factor IX consumption and lower bleeding rates.
- Recombinant factor VIII Fc fusion protein: Extended-interval dosing maintains low bleeding rates and correlates with von Willebrand Factor levels.
- Long-acting recombinant factor IX Fc fusion protein (rFIXFc) for perioperative management of subjects with haemophilia B in the phase 3 B-LONG study.
- Rituximab for treatment of inhibitors in haemophilia A. A Phase II Study.
- AntiCoagulation duration in heterozygous factor V Leiden: A decision analysis.
- Phase 3 study of recombinant factor IX Fc fusion protein in Hemophilia B.
- No increase in bleeding identified in type 1 VWD subjects with D1472H sequence variation.
- Liver transplant outcomes in HIV+ haemophilic men.
- Phase II prospective open-label trial of recombinant interleukin-11 in desmopressin-unresponsive von Willebrand disease and mild or moderate haemophilia A.
- AntiCoagulation in ambulatory cancer patients with no indication for prophylactic or therapeutic antiCoagulation. A cost-effectiveness analysis from a U.S. perspective.
- Chest pain, dyspnea, petechiae, and melena in a 58-year-old woman - What is it?
- Safety and prolonged activity of recombinant factor VIII Fc fusion protein in Hemophilia A patients.
- Von Willebrand factor mutations and new sequence variations identified in healthy controls are more frequent in the African-American population.
- Recombinant factor IX-Fc fusion protein (rFIXFc) demonstrates safety and prolonged activity in a phase 1/2a study in Hemophilia B patients.
- FVIII, CD4, and liaisons dangereuses.
- Cost-utility analysis of von Willebrand disease screening in adolescents with menorrhagia.
- Common VWF exon 28 polymorphisms in African Americans affecting the VWF activity assay by ristocetin cofactor.
- Immunomodulatory derivatives induce PU.1 down-regulation, myeloid maturation arrest, and neutropenia.
- Porcine and canine von Willebrand factor and von Willebrand disease: hemostasis, Thrombosis, and atherosclerosis studies.
- Pulmonary embolism and spiral computerized tomographic scans.
- Coagulation factor VIIa (recombinant) in nonhemophilic patients requiring neurosurgery.
- Extrahepatic factor VIII production in transplant recipient of Hemophilia donor liver.
- Genetics of bleeding Disorders in women.
- Pulmonary embolism incidence is increasing with use of spiral computed tomography.
- CD8(+) T-cell responses to adeno-associated virus capsid in humans.
- Liver transplantation in HIV-seropositive individuals.
- Bleeding Disorders in premenopausal women: (another) public health crisis for hematology?
- Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver Disease.
- Hemophilia gene transfer: comparison with conventional protein replacement therapy.
- Association of venous thromboembolism with human immunodeficiency virus and mortality in veterans.
- Survival of human immunodeficiency virus-infected liver transplant recipients.
- Phase 1 trial of FVIII gene transfer for severe Hemophilia A using a retroviral construct administered by peripheral intravenous infusion.
- AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe Hemophilia B.
- Anticardiolipin antibody associated arterial Thrombosis following fibula fracture.
- Safe passage: a plea for safety in Hemophilia gene therapy.
- Prospective, multicenter study of postoperative Deep-vein thrombosis in patients with haemophilia undergoing major orthopaedic surgery.
Schools
University of Pittsburgh Main Campus
University Of Pittsburgh Med Center
Conditions Treated
- Anemia
- Antiphospholipid Syndrome (APS)
- Coagulation Disorders (incl. Hemophilia)
- Deep Vein Thrombosis (DVT)
- View All
Doctors Specialties
- Hematology
Accepted Insurances
Education
-
UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH -
University of Pittsburgh Medical Center -
University of Pittsburgh School of Medicine
Hospital
-
UPMC Presbyterian Shadyside
Drug Facts
| NPI NUMBER | 1922073493 | |
| NPPES Provider LastName | RAGNI | |
| NPPES Provider FirstName | MARGARET | |
| NPPES Provider ZIPCode | 152321301 | |
| NPPES Provider State | PA | |
| Specialty Description | Hematology | |
| Total Claim Count | 240.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 12.0 | |
| Percent Opioid Claims | 5.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1922073493 |
| Last Name Of The Provider | RAGNI |
| First Name Of The Provider | MARGARET |
| View All |
Similar Doctors
|
|
Dr. Franklin A. Bontempo, MD
 This Doctor is OpenDoctor Recommended.
 This doctor has more publications
|
|
Dr. Leonard J. Appleman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Louis D. Pietragallo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robert L. Volkin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Craig D. Seaman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kathleen A. Dorritie, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sonam Prakash, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Andrew D. Liman, MD |
|
|
Dr. Alan N. Bress, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jing Z. Hou, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sandra A. Blakowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shahid Bokhari, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Rajiv Jain, MB |